Brief: SMS Pharma Updates On USFDA Statement On Ranitidine

SMS Pharmaceuticals

09/04/2020 15:33

April 9 (Reuters) - SMS Pharmaceuticals Ltd  SMSP.NS :
    * UPDATES ON USFDA STATEMENT IN CONNECTION WITH RANITIDINE
    * TILL DATE CO HAS NOT SOLD ANY RANITIDINE API FOR
COMMERCIAL
DISTRIBUTION IN THE U.S.
    * NO MATERIAL IMPACT ON CO'S CURRENT, FUTURE REVENUES OR
MARGINS
AS REVENUE FROM RANITIDINE IN PREVIOUS YEARS BELOW 1% OF TOTAL
REVENUE
    * COMMERCIAL SUPPLIES OF RANITIDINE HCL DRUG SUBSTANCE TO
U.S.
MARKET CURRENTLY DELAYED BY 9-10 MONTHS
    * COMMERCIAL SUPPLIES OF RANITIDINE HCL DRUG SUBSTANCE TO
U.S.
MARKET SEEN STARTING BY END OF CURRENT CALENDAR YEAR

Source text: https://bit.ly/2VgFca1
Further company coverage:  SMSP.NS 

 ((Reuters.Briefs@thomsonreuters.com;))